Other articles of interest

Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study

Pablo García-Pavía, José Manuel García-Pinilla, Ainara Lozano-Bahamonde, Sergi Yun, Antonio García-Quintana, Juan José Gavira-Gómez, Miguel Ángel Aibar-Arregui, Gonzalo Barge-Caballero, Julio Núñez Villota, Laura Bernal, Patricia Tarilonte,

Rev Esp Cardiol. 2025;78:301-10
Efficacy and safety of SGLT2 inhibitors in patients with heart failure according to kidney function: a systematic review and meta-analysis

David Hong, Minseok Hong, Onyou Kim, Heayoung Shin, Minjung Bak, Darae Kim, Jihoon Kim, Ki Hong Choi, Eun Kyoung Kim, Joo Myung Lee, Jeong Hoon Yang, Sung-A Chang, Sung-Ji Park, Sang-Chol Lee, Seung Woo Park, Jin-Oh Choi,
NT-proBNP in systemic right ventricles: a new cutoff level for risk stratification?

Fabian Tran, Francisco Javier Ruperti-Repilado, Philip Haaf, Pedro Lopez-Ayala, Matthias Greutmann, Markus Schwerzmann, Judith Bouchardy, Harald Gabriel, Dominik Stambach, Juerg Schwitter, Kerstin Wustmann, Michael Freese, Christian Mueller, Daniel Tobler,

Rev Esp Cardiol. 2025;78:107-16